CBD is listed on the Controlled Drug Register in Australia, which means that it can’t be sold as a consumer product. From June 2021, the Therapeutic Goods Administration has enabled access to such products through pharmacies, and without a prescription. This report provides a detailed overview of the current regulatory regime in place in Australia for these products, covering everything from the hemp plant itself to extracts and finished products.
If you purchase a report that is updated in the next 60 days, we will send you the new report for free.
Reasons to buyA proposal has been put forward that would change the scheduling of CBD, which in turn has a number of consequences. If this, and the Australian market in general, interests you then this is the report for you. It not only provides information on the current regulatory regime for hemp and CBD in Australia, but it also offers analysis and data about the near future, as well as insight into the current status of medical and recreational cannabis.
Table of contents
MethodologyThe research is completely original and conducted by CBD-Intel’s multilingual legal analysis team using several sources, including online and offline resources and data, specialised legal software, interviews with key stakeholders and government officials, and via the collaboration with local lawyers and on-the-ground profession.
Latest reportsCBD is listed on the Controlled Drug Register in Australia, which means that it can’t be sold as a consumer product. From June 2021, the Therapeutic Goods Administration has enabled access to such products through pharmacies, and without a prescription. This report provides a detailed overview of the current regulatory regime in place in Australia for these products, covering everything from the hemp plant itself to extracts and finished products.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.